Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 203,122,240
  • Shares Outstanding, K 2,291,800
  • Annual Sales, $ 53,166 M
  • Annual Income, $ 12,611 M
  • 60-Month Beta 0.59
  • Price/Sales 3.90
  • Price/Cash Flow 10.85
  • Price/Book 3.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.24
  • Number of Estimates 3
  • High Estimate 1.29
  • Low Estimate 1.21
  • Prior Year 1.24
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
85.60 +4.43%
on 10/14/19
89.55 -0.17%
on 11/12/19
+2.79 (+3.23%)
since 10/11/19
3-Month
83.97 +6.46%
on 10/02/19
91.38 -2.17%
on 08/13/19
-1.71 (-1.87%)
since 08/12/19
52-Week
72.19 +23.83%
on 12/27/18
95.00 -5.90%
on 07/18/19
+11.78 (+15.18%)
since 11/12/18

Most Recent Stories

More News
Roche's SMA Drug Meets Primary Endpoint in Pivotal Study

Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.

NVS : 89.41 (+0.88%)
RHHBY : 37.5100 (-0.12%)
BIIB : 290.06 (-1.39%)
PTCT : 41.94 (+1.55%)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 89.41 (+0.88%)
AXLA : 4.00 (-5.21%)
DNLI : 15.44 (+3.97%)
EVLO : 6.19 (-3.13%)
KLDO : 6.26 (+1.13%)
MRNA : 17.93 (+3.05%)
RUBY : 10.76 (-1.74%)
MCRB : 3.83 (+5.22%)
SYRS : 4.94 (-1.00%)
Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

CELGZ : 0.50 (+4.17%)
NVS : 89.41 (+0.88%)
NVO : 57.17 (-0.21%)
GNHAF : 153.9906 (-3.55%)
Sandoz presents real-world data showing effectiveness of Erelzi(R) (etanercept-szzs) in rheumatic disease treatment

- Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting

NVS : 89.41 (+0.88%)
New Novartis PREVENT data show Cosentyx(R) delivers early relief in axial spondyloarthritis

- 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1]

NVS : 89.41 (+0.88%)
Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Novartis presented phase 2 results...

MOR : 26.49 (-0.93%)
NVS : 89.41 (+0.88%)
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

NVO : 57.17 (-0.21%)
NVS : 89.41 (+0.88%)
SNY : 46.10 (+0.52%)
AGN : 183.62 (+1.12%)
JNJ : 131.36 (-0.47%)
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day

Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day

CHRW : 76.13 (-0.95%)
CHGG : 35.37 (+1.61%)
NVS : 89.41 (+0.88%)
BUD : 79.22 (+0.65%)
TLRY : 21.21 (-3.24%)
Novartis' Generics Unit to Buy Aspen's Japanese Operations

Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

MRK : 84.40 (+1.34%)
BMY : 58.86 (+1.22%)
NVS : 89.41 (+0.88%)
GSK : 44.53 (+0.61%)
Sandoz announces agreement to acquire Aspen's Japanese operations and associated assets, strengthening position in world's third largest generics market

Sandoz announces agreement to acquire Aspen's Japanese operations and associated assets, strengthening position in world's third largest generics market

NVS : 89.41 (+0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 89.19
1st Resistance Point 88.91
Last Price 89.41
1st Support Level 88.36
2nd Support Level 88.09

See More

52-Week High 95.00
Last Price 89.41
Fibonacci 61.8% 86.29
Fibonacci 50% 83.60
Fibonacci 38.2% 80.90
52-Week Low 72.19

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar